For example, silencing miR-21, which is overexpressed in BC, has been demonstrated to enhance tamoxifen or fulvestrant sensitivity by inhibiting the PI3K/AKT/mTOR pathway in ER-positive BC cells [11]. The gene discussed is AKT1; the disease is breast cancer.